Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998061910> ?p ?o ?g. }
- W1998061910 endingPage "S30" @default.
- W1998061910 startingPage "S23" @default.
- W1998061910 abstract "ADVANCE (Action in Diabetes and Vascular Disease - PreterAx and DiamicroN MR Controlled Evaluation) is a large-scale clinical trial designed to investigate the benefits of blood pressure lowering and intensive glucose control in patients with type 2 diabetes mellitus.ADVANCE is a 2 x 2 factorial randomized trial evaluating the benefits of the low-dose fixed combination of perindopril and indapamide versus placebo to lower blood pressure and of an intensive gliclazide-MR-based regimen, targeting glycosylated haemoglobin (HbA1c) levels of 6.5% or less versus standard therapy to lower blood glucose. The two primary outcomes, taken separately and jointly, are a composite macrovascular endpoint and a composite microvascular endpoint.A total of 11 140 participants were randomized between July 2001 and March 2003 from among 12 878 individuals with type 2 diabetes recruited from 215 centres in 20 countries, who entered a 6-week run-in phase. The average (SD) baseline blood pressure of 145(22)/81 (11) mmHg fell by 8/3 mmHg during the run-in phase during which participants received one tablet of open-labelled perindopril 2 mg-indapamide 0.625 mg. Only 3.6% of the 12 878 patients who entered the run-in phase withdrew because of suspected intolerance to perindopril-indapamide. With over 4 years of follow-up on average so far, over 80% of participants are still adhering to randomized therapy. Follow-up of the blood pressure arm will be completed during 2007.The safety and efficacy of perindopril-indapamide in lowering blood pressure and of a gliclazide-MR-based regimen in lowering blood glucose have been established with the completion of a 6-week run-in phase and of more than 4 years of post-randomization follow-up. It is anticipated that ADVANCE will provide many new insights including: whether blood pressure lowering with perindopril-indapamide reduces the risk of both macrovascular and microvascular events irrespective of baseline blood pressure; whether more intensive blood pressure lowering with a gliclazide-MR-based regimen targeting on HbA1c levels of 6.5% or less reduces these two outcomes compared with standard guidelines therapy; and finally whether the separate benefits of these two treatment regimens are additive." @default.
- W1998061910 created "2016-06-24" @default.
- W1998061910 creator A5016936793 @default.
- W1998061910 creator A5027520502 @default.
- W1998061910 creator A5043935096 @default.
- W1998061910 creator A5055394217 @default.
- W1998061910 creator A5085682074 @default.
- W1998061910 date "2007-06-01" @default.
- W1998061910 modified "2023-10-14" @default.
- W1998061910 title "New insights from ADVANCE" @default.
- W1998061910 cites W1502524639 @default.
- W1998061910 cites W1526132778 @default.
- W1998061910 cites W1592471891 @default.
- W1998061910 cites W1604542334 @default.
- W1998061910 cites W179126878 @default.
- W1998061910 cites W180946569 @default.
- W1998061910 cites W1965087670 @default.
- W1998061910 cites W1985203283 @default.
- W1998061910 cites W1990359844 @default.
- W1998061910 cites W2034399664 @default.
- W1998061910 cites W2035540389 @default.
- W1998061910 cites W2035617981 @default.
- W1998061910 cites W2045203451 @default.
- W1998061910 cites W2054135103 @default.
- W1998061910 cites W2072342077 @default.
- W1998061910 cites W2078089300 @default.
- W1998061910 cites W2095070268 @default.
- W1998061910 cites W2100536407 @default.
- W1998061910 cites W2105476950 @default.
- W1998061910 cites W2123946565 @default.
- W1998061910 cites W2129991662 @default.
- W1998061910 cites W2134845027 @default.
- W1998061910 cites W2137408480 @default.
- W1998061910 cites W2139634859 @default.
- W1998061910 cites W2145343804 @default.
- W1998061910 cites W2151100203 @default.
- W1998061910 cites W2156121263 @default.
- W1998061910 cites W2159426250 @default.
- W1998061910 cites W2168367179 @default.
- W1998061910 cites W2172035122 @default.
- W1998061910 cites W2172124430 @default.
- W1998061910 cites W2292780392 @default.
- W1998061910 cites W2305118939 @default.
- W1998061910 cites W2337454357 @default.
- W1998061910 cites W3022929210 @default.
- W1998061910 cites W3198570063 @default.
- W1998061910 cites W4246169631 @default.
- W1998061910 cites W4321429522 @default.
- W1998061910 doi "https://doi.org/10.1097/01.hjh.0000271506.69949.46" @default.
- W1998061910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17579315" @default.
- W1998061910 hasPublicationYear "2007" @default.
- W1998061910 type Work @default.
- W1998061910 sameAs 1998061910 @default.
- W1998061910 citedByCount "7" @default.
- W1998061910 countsByYear W19980619102012 @default.
- W1998061910 countsByYear W19980619102017 @default.
- W1998061910 crossrefType "journal-article" @default.
- W1998061910 hasAuthorship W1998061910A5016936793 @default.
- W1998061910 hasAuthorship W1998061910A5027520502 @default.
- W1998061910 hasAuthorship W1998061910A5043935096 @default.
- W1998061910 hasAuthorship W1998061910A5055394217 @default.
- W1998061910 hasAuthorship W1998061910A5085682074 @default.
- W1998061910 hasConcept C126322002 @default.
- W1998061910 hasConcept C134018914 @default.
- W1998061910 hasConcept C142724271 @default.
- W1998061910 hasConcept C168563851 @default.
- W1998061910 hasConcept C203092338 @default.
- W1998061910 hasConcept C204787440 @default.
- W1998061910 hasConcept C27081682 @default.
- W1998061910 hasConcept C2777180221 @default.
- W1998061910 hasConcept C2777448766 @default.
- W1998061910 hasConcept C2777748223 @default.
- W1998061910 hasConcept C2779200603 @default.
- W1998061910 hasConcept C2781413609 @default.
- W1998061910 hasConcept C555293320 @default.
- W1998061910 hasConcept C71924100 @default.
- W1998061910 hasConcept C84393581 @default.
- W1998061910 hasConceptScore W1998061910C126322002 @default.
- W1998061910 hasConceptScore W1998061910C134018914 @default.
- W1998061910 hasConceptScore W1998061910C142724271 @default.
- W1998061910 hasConceptScore W1998061910C168563851 @default.
- W1998061910 hasConceptScore W1998061910C203092338 @default.
- W1998061910 hasConceptScore W1998061910C204787440 @default.
- W1998061910 hasConceptScore W1998061910C27081682 @default.
- W1998061910 hasConceptScore W1998061910C2777180221 @default.
- W1998061910 hasConceptScore W1998061910C2777448766 @default.
- W1998061910 hasConceptScore W1998061910C2777748223 @default.
- W1998061910 hasConceptScore W1998061910C2779200603 @default.
- W1998061910 hasConceptScore W1998061910C2781413609 @default.
- W1998061910 hasConceptScore W1998061910C555293320 @default.
- W1998061910 hasConceptScore W1998061910C71924100 @default.
- W1998061910 hasConceptScore W1998061910C84393581 @default.
- W1998061910 hasIssue "Suppl 1" @default.
- W1998061910 hasLocation W19980619101 @default.
- W1998061910 hasLocation W19980619102 @default.
- W1998061910 hasOpenAccess W1998061910 @default.
- W1998061910 hasPrimaryLocation W19980619101 @default.
- W1998061910 hasRelatedWork W1968246179 @default.